TY - JOUR
T1 - Targeted dietary interventions to reduce pain in persistent post-traumatic headache among service members
T2 - Protocol for a randomized, controlled parallel-group trial
AU - Faurot, Keturah R.
AU - Cole, Wesley R.
AU - MacIntosh, Beth A.
AU - Dunlap, Margaret
AU - Moore, Carol B.
AU - Roberson, Brittney
AU - Guerra, Melissa
AU - Domenichiello, Anthony F.
AU - Palsson, Olafur
AU - Rivera, Wanda
AU - Nothwehr, Ann
AU - Arrieux, Jacques
AU - Russell, Katie
AU - Jones, Cecily
AU - Werner, J. Kent
AU - Clark, Ruth
AU - Diaz-Arrastia, Ramon
AU - Suchindran, Chirayath
AU - Mann, J. Douglas
AU - Ramsden, Christopher E.
AU - Kenney, Kimbra
N1 - Publisher Copyright:
© 2022 Elsevier Inc.
PY - 2022/8
Y1 - 2022/8
N2 - Introduction: Post-traumatic headache (PTH) is common after traumatic brain injury (TBI), especially among active-duty service members (SMs), affecting up to 35% of patients with chronic TBI. Persistent PTH is disabling and frequently unresponsive to treatment and is often migrainous. Here, we describe a trial assessing whether dietary modifications to increase n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and reduce n-6 linoleic acid (LA), will alter nociceptive lipid mediators and result in clinical improvements in persistent PTH. Methods: This prospective, randomized, controlled trial tests the efficacy, safety, and biochemical effects of targeted, controlled alterations in dietary n-3 and n-6 fatty acids in 122 adult SMs and military healthcare beneficiaries with diagnosed TBI associated with actively managed persistent frequent (>8 /month) PTH with migraine. Following a 4-week baseline, participants are randomized to one of two equally intensive dietary regimens for 12 additional weeks: 1) increased n-3 EPA + DHA with low n-6 LA (H3L6); 2) usual US dietary content of n-3 and n-6 fatty acids (Control). During the intervention, participants receive diet arm-specific study oils and foods sufficient for 75% of caloric needs and comprehensive dietary counseling. Participants complete daily headache diaries throughout the intervention. Clinical outcomes, including the Headache Impact Test (HIT-6), headache hours per day, circulating blood fatty acid levels, and bioactive metabolites, are measured pre-randomization and at 6 and 12 weeks. Planned primary analyses include pre-post comparisons of treatment groups on clinical measures using ANCOVA and mixed-effects models. Similar approaches to explore biochemical and exploratory clinical outcomes are planned. ClinicalTrials.gov
AB - Introduction: Post-traumatic headache (PTH) is common after traumatic brain injury (TBI), especially among active-duty service members (SMs), affecting up to 35% of patients with chronic TBI. Persistent PTH is disabling and frequently unresponsive to treatment and is often migrainous. Here, we describe a trial assessing whether dietary modifications to increase n-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and reduce n-6 linoleic acid (LA), will alter nociceptive lipid mediators and result in clinical improvements in persistent PTH. Methods: This prospective, randomized, controlled trial tests the efficacy, safety, and biochemical effects of targeted, controlled alterations in dietary n-3 and n-6 fatty acids in 122 adult SMs and military healthcare beneficiaries with diagnosed TBI associated with actively managed persistent frequent (>8 /month) PTH with migraine. Following a 4-week baseline, participants are randomized to one of two equally intensive dietary regimens for 12 additional weeks: 1) increased n-3 EPA + DHA with low n-6 LA (H3L6); 2) usual US dietary content of n-3 and n-6 fatty acids (Control). During the intervention, participants receive diet arm-specific study oils and foods sufficient for 75% of caloric needs and comprehensive dietary counseling. Participants complete daily headache diaries throughout the intervention. Clinical outcomes, including the Headache Impact Test (HIT-6), headache hours per day, circulating blood fatty acid levels, and bioactive metabolites, are measured pre-randomization and at 6 and 12 weeks. Planned primary analyses include pre-post comparisons of treatment groups on clinical measures using ANCOVA and mixed-effects models. Similar approaches to explore biochemical and exploratory clinical outcomes are planned. ClinicalTrials.gov
KW - Omega-3 fatty acid
KW - Omega-6 fatty acid
KW - Post-traumatic headache
KW - Traumatic brain injury
UR - http://www.scopus.com/inward/record.url?scp=85135115590&partnerID=8YFLogxK
U2 - 10.1016/j.cct.2022.106851
DO - 10.1016/j.cct.2022.106851
M3 - Article
C2 - 35842107
AN - SCOPUS:85135115590
SN - 1551-7144
VL - 119
JO - Contemporary Clinical Trials
JF - Contemporary Clinical Trials
M1 - 106851
ER -